Labcorp (NYSE: LH) executives to speak at Morgan Stanley Global Healthcare Conference

Rhea-AI Filing Summary

Labcorp Holdings Inc. announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The session is scheduled for Tuesday, September 9, at 7:45 a.m. ET and will focus on the company’s role as a global provider of innovative and comprehensive laboratory services.

A live audio webcast of the discussion will be available through Labcorp’s investor relations website at ir.Labcorp.com, and the recording will be archived for replay. The company furnished a related press release as Exhibit 99.1 to this report.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000920148false00009201482025-08-272025-08-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

August 27, 2025

(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

1-11353

99-2588107

(State or other jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

358 South Main Street

Burlington

,

North Carolina

27215

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number including area code) 336-229-1127

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, $0.10 par value

LH

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).             

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on August 27, 2025 that members of the executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, at 7:45 am ET. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.

A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay.

Item 9.01			Financial Statements and Exhibits.
Exhibit			Exhibit Name
Exhibit 99.1			Press Release dated August 27, 2025 issued by Labcorp Holdings Inc.
Exhibit 104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.

Registrant

Date: August 28, 2025			By:			/s/ SANDRA D. VAN DER VAART
						Sandra D. van der Vaart
						Executive Vice President, Chief Legal Officer and Corporate Secretary

FAQ

What did Labcorp (LH) disclose in this 8-K filing?

Labcorp disclosed that its executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference, with details provided in a press release furnished as Exhibit 99.1.

When will Labcorp’s fireside chat at the Morgan Stanley Global Healthcare Conference take place?

The fireside chat is scheduled for Tuesday, September 9, at 7:45 a.m. ET.

How can investors listen to Labcorp’s conference fireside chat?

A live audio webcast of the fireside chat will be available on Labcorp’s investor relations website at ir.Labcorp.com, and it will be archived for replay.

What exhibit did Labcorp include with this 8-K filing?

Labcorp included Exhibit 99.1, which is a press release dated August 27, 2025, along with Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

Does this Labcorp (LH) 8-K include new financial results?

No, this 8-K focuses on Labcorp’s participation in an investor conference and the availability of a webcast, and does not present financial statements or earnings data.

What role does the Labcorp executive signing the 8-K hold?

The 8-K is signed by Sandra D. van der Vaart, who serves as Executive Vice President, Chief Legal Officer and Corporate Secretary of Labcorp Holdings Inc.